Who are Intra-nasal Dexmedetomidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mirtazapine Tablets, Methadone-dexmedetomidine-ketamine combination, Group D : Dexmedetomidine + propofol group, Dexmedetomidine (DEX), Normal saline, Lidocaine, dexmetomidine, Norepinephrine (Levophed).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intra-nasal-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intra-nasal Dexmedetomidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra-nasal Dexmedetomidine (Intra-nasal Dexmedetomidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Anesthesia/Sedation.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Anesthesia/Sedation Small molecule Live · refreshed every 30 min

Target snapshot

Intra-nasal Dexmedetomidine (Intra-nasal Dexmedetomidine) — University of Massachusetts, Worcester. Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intra-nasal Dexmedetomidine TARGET	Intra-nasal Dexmedetomidine	University of Massachusetts, Worcester	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Mirtazapine Tablets	Mirtazapine Tablets	National Institute of Mental Health, Dhaka	marketed	Tetracyclic antidepressant	Alpha-2 adrenergic receptor, 5-HT2 receptor, 5-HT3 receptor
Methadone-dexmedetomidine-ketamine combination	Methadone-dexmedetomidine-ketamine combination	University of Missouri-Columbia	marketed	Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist)	Mu opioid receptor, alpha-2 adrenergic receptor, NMDA receptor
Group D : Dexmedetomidine + propofol group	Group D : Dexmedetomidine + propofol group	Seoul National University Hospital	marketed	Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist)	Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
Dexmedetomidine (DEX)	Dexmedetomidine (DEX)	Ain Shams University	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Normal saline, Lidocaine, dexmetomidine	Normal saline, Lidocaine, dexmetomidine	Kasr El Aini Hospital	marketed	Local anesthetic combination with sedative-analgesic agent	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intra-nasal Dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/intra-nasal-dexmedetomidine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab